NGL Fine-Chem Limited
NSE: NGLFINE BSE: NGLFINE
Prev Close
1093.9
Open Price
1090
Volume
493
Today Low / High
1056.3 / 1100
52 WK Low / High
957 / 2777.95
Range
1,017 - 1,124
Prev Close
1080
Open Price
1090
Volume
36
Today Low / High
1090 / 1119
52 WK Low / High
962.7 / 2774.4
Range
1,061 - 1,173
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1070 (target range: 1,017 - 1,124), reflecting a change of -23.9 (-2.18484%). On the BSE, it is listed at 1116.95 (target range: 1,061 - 1,173), showing a change of 36.95 (3.4213%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
NGL Fine-Chem Limited Graph
NGL Fine-Chem Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for NGL Fine-Chem Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,070.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 1,116.95 | 1,128.12 | 1,015.31 - 1,240.93 |
1,139.29 | 911.43 - 1,367.15 | ||
1,150.46 | 805.32 - 1,495.60 | ||
Bearish Scenario | 1,116.95 | 1,105.78 | 995.20 - 1,216.36 |
1,094.61 | 875.69 - 1,313.53 | ||
1,083.44 | 758.41 - 1,408.47 |
Overview of NGL Fine-Chem Limited
ISIN
INE887E01022
Industry
Drug Manufacturers - General
Vol.Avg
11,444
Market Cap
6,610,481,400
Last Dividend
1.75
Official Website
IPO Date
2022-07-08
DCF Diff
1,647.56
DCF
-575
Financial Ratios Every Investor Needs
Stock Dividend of NGLFINE
Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|---|
2024-08-16 | August 16, 24 | 1.75 | 1.75 | 2024-08-16 | 2024-09-22 | |
2023-08-17 | August 17, 23 | 1.75 | 1.75 | 2023-08-18 | 2023-09-24 | |
2022-06-22 | June 22, 22 | 1.75 | 1.75 | 2022-06-23 | 2022-07-30 | |
2021-08-12 | August 12, 21 | 1.75 | 1.75 | 2021-08-13 | 2021-09-19 | |
2020-08-06 | August 06, 20 | 1.75 | 1.75 | 2020-08-07 | 2020-09-13 |
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 333.71 Cr | 270.06 Cr | 63.65 Cr | 0.1907 | 7.76 Cr | 6.21 Cr | 41.63 Cr | 41.32 Cr | 66.88 | 67.87 Cr | 0.1238 |
2023-03-31 | 278.08 Cr | 140.32 Cr | 137.76 Cr | 0.4954 | 5.32 Cr | 38.49 Cr | 23.03 Cr | 20.50 Cr | 33.18 | 40.49 Cr | 0.0737 |
2022-03-31 | 312.83 Cr | 146.99 Cr | 165.84 Cr | 0.5301 | 4.27 Cr | 3.84 Cr | 57.48 Cr | 49.90 Cr | 80.77 | 78.88 Cr | 0.1595 |
2021-03-31 | 255.00 Cr | 102.34 Cr | 152.66 Cr | 0.5987 | 3.28 Cr | 3.26 Cr | 75.96 Cr | 56.72 Cr | 91.81 | 88.13 Cr | 0.2224 |
2020-03-31 | 148.95 Cr | 64.37 Cr | 84.59 Cr | 0.5679 | 3.76 Cr | 3.40 Cr | 13.52 Cr | 8.34 Cr | 13.49 | 22.81 Cr | 0.0560 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 0.40 Cr | 355.54 Cr | 92.90 Cr | 262.6319 Cr | 34.00 Cr | 33.61 Cr | 43.30 Cr | 130.82 Cr | 0.00 Cr | 0.00 Cr | 4.62 Cr | 86.5872 Cr |
2023-03-31 | 7.83 Cr | 287.08 Cr | 64.53 Cr | 222.5491 Cr | 30.48 Cr | 22.65 Cr | 26.99 Cr | 113.90 Cr | 5.30 Cr | 2.70 Cr | 4.39 Cr | 58.2917 Cr |
2022-03-31 | 0.64 Cr | 276.93 Cr | 73.71 Cr | 203.2179 Cr | 30.00 Cr | 29.36 Cr | 56.01 Cr | 94.75 Cr | 1.93 Cr | 2.55 Cr | 2.57 Cr | 65.6504 Cr |
2021-03-31 | 2.10 Cr | 207.77 Cr | 53.31 Cr | 154.4578 Cr | 16.45 Cr | 14.35 Cr | 37.85 Cr | 75.98 Cr | 2.29 Cr | 2.46 Cr | -27.11 Cr | 42.1431 Cr |
2020-03-31 | 0.40 Cr | 153.62 Cr | 54.66 Cr | 98.9608 Cr | 28.23 Cr | 27.83 Cr | 27.90 Cr | 67.35 Cr | -19.91 Cr | 2.11 Cr | -0.74 Cr | 43.0389 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 20.4653 Cr | -26.8173 Cr | -1.0812 Cr | -8.0588 Cr | -7.4332 Cr | 0.3952 Cr | -28.5241 Cr | 41.3167 Cr | 0.0000 Cr | -1.0812 Cr | -16.3102 Cr |
2023-03-31 | 35.2862 Cr | -27.0204 Cr | -1.0812 Cr | 3.8795 Cr | 7.1846 Cr | 7.8284 Cr | -31.4067 Cr | 27.3620 Cr | 0.0000 Cr | -1.0812 Cr | 29.0143 Cr |
2022-03-31 | 13.8246 Cr | -14.2030 Cr | -1.0812 Cr | -42.5518 Cr | -1.4595 Cr | 0.6438 Cr | -56.3764 Cr | 66.5964 Cr | 0.0000 Cr | -1.0812 Cr | -18.1570 Cr |
2021-03-31 | 27.3541 Cr | -24.5685 Cr | -1.0812 Cr | 10.1422 Cr | 1.7044 Cr | 2.1033 Cr | -17.2119 Cr | 77.5895 Cr | 0.0000 Cr | -1.0812 Cr | -9.9537 Cr |
2020-03-31 | 20.4644 Cr | -20.8545 Cr | -1.3034 Cr | 5.5489 Cr | -0.3901 Cr | 0.3989 Cr | -14.9155 Cr | 12.0723 Cr | 0.0000 Cr | -1.3034 Cr | -9.2867 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 89.10 Cr | 43.53 Cr | 45.57 Cr | 0.5115 | 2.00 Cr | 1.27 Cr | 2.07 | 4.96 Cr | 0.0143 |
2024-09-30 | 93.48 Cr | 44.18 Cr | 49.31 Cr | 0.5275 | 8.53 Cr | 9.81 Cr | 15.88 | 16.67 Cr | 0.1050 |
2024-06-30 | 90.75 Cr | 62.09 Cr | 28.66 Cr | 0.3158 | 31.66 Cr | 9.22 Cr | 14.92 | 9.35 Cr | 0.1016 |
2024-03-31 | 99.76 Cr | 62.32 Cr | 37.44 Cr | 0.3753 | 12.90 Cr | 12.30 Cr | 19.95 | 19.50 Cr | 0.1233 |
2023-12-31 | 87.95 Cr | 55.71 Cr | 32.24 Cr | 0.3665 | 10.92 Cr | 10.03 Cr | 16.24 | 13.87 Cr | 0.1141 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2024-09-30 | 6.00 Cr | 92.99 Cr | 98.99 Cr | 0.00 Cr | 43.46 Cr | 235.28 Cr | 149.37 Cr | 395.85 Cr | 115.56 Cr |
2024-06-30 | 0.00 Cr | 0.00 Cr | 55.31 Cr | 0.00 Cr | 0.00 Cr | 55.31 Cr | 0.00 Cr | 0.00 Cr | -262.63 Cr |
2024-03-31 | 1.72 Cr | 53.59 Cr | 55.31 Cr | 90.37 Cr | 43.30 Cr | 212.67 Cr | 130.82 Cr | 355.54 Cr | 92.90 Cr |
2023-12-31 | -64.11 Cr | 128.22 Cr | 64.11 Cr | 0.00 Cr | 0.00 Cr | 64.11 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-09-30 | 0.75 Cr | 70.83 Cr | 71.58 Cr | 69.99 Cr | 38.84 Cr | 193.77 Cr | 119.26 Cr | 322.88 Cr | 81.26 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-06-30 | 9.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | 12.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | 10.03 Cr | 5.89 Cr | 0.00 Cr | 0.00 Cr | 5.89 Cr | 6.63 Cr | 0.75 Cr | 0.00 Cr | 5.89 Cr |
2023-09-30 | 10.48 Cr | 5.78 Cr | 0.00 Cr | 0.00 Cr | 5.78 Cr | 0.75 Cr | -5.03 Cr | 0.00 Cr | 5.78 Cr |
2023-06-30 | 8.51 Cr | 5.72 Cr | 0.00 Cr | 0.00 Cr | 5.72 Cr | 13.55 Cr | 7.83 Cr | 0.00 Cr | 5.72 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - General
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Cipla Limited | CIPLA | ₹1,530.00 | ₹1,235,689,200,000.00 | ₹2,020,145.00 |
Abbott India Limited | ABBOTINDIA | ₹30,700.00 | ₹652,353,510,000.00 | ₹6,682.00 |
GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,862.00 | ₹484,839,972,000.00 | ₹212,531.00 |
Gland Pharma Limited | GLAND | ₹1,405.00 | ₹231,482,180,000.00 | ₹105,351.00 |
Pfizer Limited | PFIZER | ₹4,295.00 | ₹196,486,371,500.00 | ₹14,347.00 |
Sanofi India Limited | SANOFI | ₹5,950.00 | ₹137,028,500,000.00 | ₹13,744.00 |
Marksans Pharma Limited | MARKSANS | ₹223.00 | ₹101,055,572,000.00 | ₹1,763,766.00 |
Key Executives
Gender: male
Year Born: 1964
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1976
FAQs about NGL Fine-Chem Limited
The CEO is Mr. Rahul Jayant Nachane.
The current price is ₹1,070.00.
The range is ₹957-2777.95.
The market capitalization is ₹661.05 crores.
The dividend yield is 0.16%.
The P/E ratio is 20.14.
The company operates in the Healthcare sector.
Overview of NGL Fine-Chem Limited (ISIN: INE887E01022) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹661.05 crores and an average daily volume of 11,444 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹1.75.